SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


 [x]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934.

                 For the quarterly period ended January 31, 1998

                                       OR

 [ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         ACT OF 1934.

            For the transition period from________________to________________


                         Commission file number 2-86360



                                INFORMEDICS, INC.
         (Exact name of small business issuer as specified in its charter)

                 Oregon                                93-0750571

          (State of incorporation)        (I.R.S. Employer Identification No.)



                4000 Kruse  Way  Place,  Bldg 3,  Suite 300,   
                         Lake   Oswego,   OR   97035
            (Address  of  principal  executive offices)

                Issuer's telephone number: (503) 697-3000

Check  whether  the issuer  (1) has filed all  reports  required  to be filed 
by Section 13 or 15(d) of the Securities  Exchange Act of 1934 during the
preceding 12 months (or for such shorter  period that the issuer was required 
to file such reports),  and (2) has been subject to such filing  requirements
for the past 90 days. Yes /X/ No/ /

Number  of  shares of  Informedics,  Inc. $.01  par  value  common  stock  
outstanding  as of  February  28,  1998:  2,674,502.



<PAGE>




                                INFORMEDICS, INC.


                         Part I - Financial Information




          The   information   included  herein  is  unaudited.   However,   such
 information  reflects all adjustments  (consisting solely of normal,  recurring
 adjustments)  which are, in the  opinion of  management,  necessary  for a fair
 presentation of the results of operations for the interim periods.  The interim
 financial  information and notes thereto should be read in conjunction with the
 Company's  latest annual report on Form 10-KSB.  The results of operations  for
 the three  months  ended  January 31, 1998 are not  necessarily  indicative  of
 results to be expected for the entire year.



<PAGE>
<TABLE>
<CAPTION>



INFORMEDICS,  INC.
STATEMENTS OF OPERATIONS

                                                                                   Three Months Ended January 31,  
                                                                                -------------------------------------
                                                                                      1998              1997

                                                                                -----------------   -----------------
<S>                                                                               <C>                   <C> 

REVENUE:
Product Sales                                                                      $  162,661           $  149,761
Customer Service and Support                                                          641,109              695,935
                                                                                -----------------   ------------------

Total Revenue                                                                         803,770              845,696
                                                                                -----------------   ------------------

COSTS AND EXPENSES:
Cost of Products Sold                                                                  37,124               28,211
Cost of Customer Service and Support                                                  234,275              501,086
Selling & Administrative Expenses                                                     275,502              485,147
Depreciation & Amortization                                                            61,017              101,610
                                                                                -----------------   ------------------

Total Costs and Expenses                                                              607,918            1,116,054
                                                                                -----------------   ------------------

Operating  Profit (Loss)                                                              195,852             (270,358)
                                                                                -----------------   ------------------

OTHER INCOME (EXPENSE):
Interest Expense                                                                         (832)              (3,835)
Interest Income                                                                         3,326                8,680
Other Income                                                                            7,279                3,669
                                                                                -----------------   ------------------

Total Other Income - Net                                                                9,773                8,514
                                                                                -----------------   ------------------

PROFIT (LOSS) BEFORE INCOME TAXES                                                     205,625             (261,844)

Income Tax                                                                             17,100                  ---
Provision
                                                                                -----------------   ------------------

NET PROFIT (L0SS) AFTER INCOME                                                     $  188,525           ($ 261,844)
TAXES
                                                                                =================   ==================

Weighted Average Number of Common Shares
Outstanding and Common Stock
Equivalents Outstanding                                                             2,674,502            2,650,307
                                                                                =================   ==================


BASIC EARNINGS (LOSS) PER SHARE                                                         $0.07               ($0.10)
                                                                                =================   ==================


DILUTED EARNINGS (LOSS) PER SHARE                                                       $0.06               ($0.08)
                                                                                =================   ==================



See Notes to Financial Statements.
</TABLE>

<PAGE>

INFORMEDICS, INC.
BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                            January 31,         October 31,
ASSETS                                                                        1998                1997
                                                                           ---------------    -----------------
                                                                                              
<S>                                                                           <C>                  <C>        

CURRENT ASSETS:

Cash                                                                          $  337,637           $  207,692
Accounts Receivable, Less Allowance  for Doubtful
   Accounts of $  16,200 in 1998 and 1997                                        948,992              445,879
Inventories                                                                        2,597                3,304
Prepaid Expenses and Other Current Assets                                         82,814               55,267
Deferred Income Taxes                                                             74,900               90,500
Current Portion of Long-Term                                                      11,928               11,928
Receivable
                                                                           ---------------    -----------------

Total Current Assets                                                           1,458,868              814,570
                                                                           ---------------    -----------------

FIXED ASSETS:

Furniture and Fixtures                                                           131,608              135,505
Machinery and Equipment                                                          440,203              557,188
Leasehold Improvements                                                            29,583               27,258
Other Fixed Assets                                                               142,982              142,982
                                                                           ---------------    -----------------
                                                                                 744,376              862,933


Less accumulated depreciation and amortization                                   649,808              737,093
                                                                           ---------------    -----------------

Total Fixed Assets                                                                94,568              125,840
                                                                           ---------------    -----------------


OTHER ASSETS:

Long-Term Account Receivable                                                      27,832               30,814
Software Development Costs,
   Less Accumulated  Amortization of $ 825,312
   in 1998 and $ 787,791 in 1997                                                 164,394              169,540
Covenants Not to Compete,
   Less Accumulated Amortization of $ 493,912
   in 1998 and $ 493,862 in 1997                                                     133                  183
Deferred Income Taxes                                                            871,401              932,901
Tax Valuation Allowance                                                         (871,401)            (932,901)
Other                                                                             39,299               39,799
                                                                           ---------------    -----------------


Total Other Assets                                                               231,658              240,336
                                                                           ---------------    -----------------


TOTAL ASSETS                                                                $  1,785,094         $  1,180,746
                                                                           ===============    =================

See Notes to Financial Statements

</TABLE>


<PAGE>






INFORMEDICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>



                                                                           January 31,          October 31,
   LIABILITIES AND STOCKHOLDERS' DEFICIT                                       1997                1997
   --------------------------------------------------------------------  -----------------    ----------------

<S>                                                                           <C>                  <C> 

   CURRENT LIABILITIES:

   Accounts Payable and Accrued Expenses:
      Trade Accounts                                                          $  147,756           $  87,917
      Customer Deposits                                                           15,810              22,590
      Accrued Wages, Payroll Taxes and Employee Benefits                          66,836              86,362
      Other Accrued Liabilities                                                    8,457               9,445
   Deferred Revenue                                                            1,554,072           1,192,368
   Current Portion of Deferred Rent                                               14,119              13,033
                                                                         -----------------  -----------------

   Total Current Liabilities                                                   1,807,050           1,411,715

   LONG-TERM OBLIGATIONS:

   Deferred Rent                                                                  13,033              17,378
   Deferred Tax Liability                                                         18,200              16,700
                                                                         -----------------  -----------------

   Total Current Liabilities and Long-Term Obligations                         1,838,283           1,445,793
                                                                         -----------------  -----------------

   STOCKHOLDERS' DEFICIT:

   Preferred Stock, $ .01 Par Value:
      Authorized 5,000,000 Shares;
      No Shares Outstanding                                                          ---                ----
   Common Stock, $.01 Par Value:
      Authorized 15,000,000 Shares;
      Shares Outstanding:  2,674,502 in 1998 and
       2,654,708 in 1997                                                          26,745              26,546
   Capital in Excess of Par Value                                              1,941,176           1,918,042
   Note Receivable from Stockholder                                              (22,000)            (22,000)
   Accumulated Deficit                                                        (1,999,110)         (2,187,635)
                                                                         -----------------   -----------------

   Total Stockholders' Deficit                                                   (53,189)           (265,047)
                                                                         -----------------   -----------------


   TOTAL LIABILITIES AND STOCKHOLDERS'
     DEFICIT                                                                $  1,785,094        $  1,180,746
                                                                         =================   =================




   See Notes to Financial Statements.


</TABLE>

<PAGE>

<TABLE>
<CAPTION>

INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS
                                                                          Three Months Ended January 31,

                                                                       -----------------------------------------
                                                                             1998                   1997
                                                                       -----------------------------------------
<S>                                                                          <C>                  <C>

CASH FLOWS FROM OPERATING ACTIVITIES:

  Net Income (Loss)                                                          $  188,525            ($  261,844)

ADJUSTMENTS TO RECONCILE NET INCOME
(LOSS) TO NET CASH AND CASH EQUIVALENTS PROVIDED BY (USED IN)
OPERATING ACTIVITIES:
 Depreciation and Amortization                                                   61,017                101,610
 Provision for Write-offs of Accounts Receivable                                    ---                  3,023
 Deferred Income Taxes                                                           17,100
 Gain on Sale of Assets                                                             ---                 (3,567)
 Changes in Assets and Liabilities:
   Accounts Receivable                                                         (503,113)                99,380
   Inventories                                                                      707                  5,407
   Prepaid Expenses and Other Current Assets                                    (27,547)                (2,552)
   Accounts Payable and Accrued Expenses                                         32,545                (40,334)
   Notes Receivable                                                               2,982                  9,499
   Deferred Revenue                                                             361,704                292,095
   Deferred Rent                                                                 (3,259)                (3,258)
                                                                       ------------------     ------------------
Net Cash and Cash Equivalents Provided by
   Operating Activities                                                         130,661                199,459
                                                                       ------------------     ------------------

INVESTING ACTIVITIES:
 Property Additions                                                              (2,325)                (4,815)
 Capitalized Software Development Costs                                         (32,374)               (25,158)
 Other                                                                           10,650                  2,517
                                                                       ------------------     ------------------
 Net Cash Used in Investing Activities                                          (24,049)               (27,456)
                                                                       ------------------     ------------------


FINANCING ACTIVITIES:
 Decrease in Revolving Line of Credit                                               ---               (125,000)
 Proceeds from Issuance of Common Stock                                          23,333                    ---
                                                                       ------------------     ------------------
  Net Cash Provided by (Used In) Financing Activities                             23,333              (125,000)
                                                                       ------------------     ------------------

NET INCREASE IN CASH AND CASH EQUIVALENTS                                       129,945                 47,003

CASH AND CASH EQUIVALENTS AT BEGINNING
   OF QUARTER                                                                   207,692                323,217
                                                                       ------------------     ------------------

CASH AND CASH EQUIVALENTS AT END
   OF QUARTER                                                                $  337,637              $ 370,220
                                                                       ==================     ==================

</TABLE>


<PAGE>


 INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>


                                                                       Three Months Ended January 31,
                                                                 -------------------------------------------
                                                                        1998                    1997
                                                                 -------------------------------------------

<S>                                                                        <C>                 <C>                 

Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                                                   $  832            $     3,835

 Income Taxes Paid (Received)                                                  ---                    ---





















See Notes to Financial Statements.

</TABLE>


<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


1.       SIGNIFICANT ACCOUNTING POLICIES

         Industry Segment
         ----------------
         The Company derives its revenue solely from the sales and servicing of
         microcomputer software and related hardware.

         Inventories
         -----------
         Inventories  are  stated  at the  lower  of cost or  market.  Specific
         identification is used to determine the costs of hardware and software
         inventory.

         Fixed Assets
         ------------
         Fixed assets are stated at cost,  less  accumulated  depreciation  and
         amortization.  The  costs of fixed  assets  are  depreciated  over the
         estimated  useful  lives (two to five  years) of the assets  using the
         straight-line  method.  Leasehold  improvements are amortized over the
         term of the lease (five years).

         Customer Service and Support Revenue
         ------------------------------------
         Customer  service and support revenue  represents  revenue earned from
         hardware and software maintenance contracts, training, installation of
         new systems,  and general  software  support and programming  services
         provided to customers.  Under  renewable  maintenance  contracts,  the
         Company  provides,  for a term of  generally  not more  than one year,
         essentially all maintenance and repairs  resulting from the normal and
         intended  use  of  its  products.   Deferred  revenue  on  maintenance
         contracts is amortized  by the  straight-line  method over the life of
         the contracts.

         Revenue Recognition
         -------------------
         Revenue from sales of software and hardware is generally recorded when
         the product is shipped.  Revenue from custom software products,  which
         are  marketed  to  customers   primarily   under   perpetual   license
         arrangements,  is recorded at the time the  product is  installed  and
         accepted by the customer. Revenue from services other than maintenance
         contracts is recognized as performed.

         Income Taxes
         ------------
         Income taxes are accounted for using the methodology established by
         Statement of Financial Accounting Standards ("SFAS") No. 109,
         "Accounting for Income Taxes," which requires an asset and aliability
         approach  to  financial  accounting and reporting  for income  taxes.
         Deferred income tax assets and liabilities are computed for 
         differences between the financial statement and tax bases of assets
         and liabilities that will result in taxable or deductible amounts in 
         the  future.  A valuation  allowance is established  when necessary 
         to reduce deferred tax assets to amounts expected to be realized,  
         based on enacted tax laws and rates applicable to the periods in which
         the differences are expected to affect taxable income. Income tax 
         expense or benefit is the tax payable or refundable for the period,
         plus or minus the change during the period in deferred tax assets and
         liabilities.



<PAGE>


INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


         Software Development Costs
         --------------------------
         Certain software development costs are being capitalized and amortized
         over the estimated  economic life of the software,  on a straight-line
         method,  commencing  when each product or enhancement is available for
         general release.  Amortization using the straight-line  method for the
         three-month periods ended January 31, 1998 and 1997 was $ 37,521 and $
         60,520 respectively.

         Covenants Not to Compete
         ------------------------
         Covenants  not to  compete  are  stated at the  estimated  value of the
         consideration  given for the covenants  (including the present value of
         any future payments to be made under each agreement),  less accumulated
         amortization.  The costs of the covenants are being amortized over four
         or seven years,  using the straight-line  method.  Amortization for the
         three-month  periods  ended  January  31,  1998  and 1997 was $50 and $
         3,859, respectively.

         Earnings  Per Share
         -------------------
         Earnings per share is computed on the basis of weighted  average number
         of shares  outstanding plus common stock  equivalents which would arise
         from  the  exercise  of  stock  options  and  warrants.   Common  stock
         equivalents are excluded from the calculation of net loss per share for
         the  nine  months  ended  January  31,  1998  and  1997,  as  they  are
         antidilutive.

         Cash and Cash Equivalents
         -------------------------
         The Company considers cash on hand, deposits in bank and highly liquid
         debt  instruments  purchased  with  original  maturity  dates of three
         months or less, as cash.

         Accounting Changes
         ------------------
         In October 1995, the Financial Accounting Standards Board (the "FASB")
         issued SFAS No. 123, "Accounting for Stock-Based  Compensation." This
         statement   establishes  an  alternative  method  of  accounting  that
         requires  recognizing  as  expense  the fair value of  employee  stock
         options and other  stock-based  awards at the grant date. SFAS No. 123
         also allows the continuation of the current accounting treatment under
         which the  Company  does not  recognize  compensation  expense for the
         stock options it awards to employees. Since the Company is electing to
         retain  its  current  method,  it is  required  to  present  pro forma
         disclosures  in its annual  financial  statements as if the fair value
         based method had been applied.

         In February 1997, the FASB issued SFAS No. 128,  "Earnings per Share."
         SFAS No. 128 requires all companies whose capital  structures  include
         convertible  securities  and  options to make a dual  presentation  of
         basic and  diluted  earnings  per share  ("EPS") in the  statement  of
         operations   and  requires   additional   disclosures   regarding  the
         computation  of  EPS.  The  new  standard  is  effective  for  interim
         statements  issued after December 15, 1997. The effect on earnings per
         share for all periods reported is immaterial.

         In June 1997, the FASB issued SFAS No. 130, "Reporting Comprehensive
         Income."  SFAS No.130 establishes requirements for disclosure of 
         comprehensive income and becomes effective for the Company's fiscal 
         year ending October 31, 1999. Reclassification of earlier financial

<PAGE>

INFORMEDICS, INC.
NOTES  TO FINANCIAL STATEMENTS


         statements for comparative purposes is required.  The impact on the
         Company's financial statements is not expected to be material.

         In June 1997, the FASB issued SFAS No. 131, "Disclosure about Segments
         of an Enterprise and Related  Information."  SFAS No. 131  establishes
         standards for disclosure about operating  segments in annual financial
         statements and selected  information in interim financial reports.  It
         also establishes  standards for related disclosures about products and
         services,  geographic  areas,  and  major  customers.  This  statement
         supersedes  SFAS  No.  14,  "Financial  Reporting  for  Segments  of a
         Business  Enterprise."  The new  standard  becomes  effective  for the
         Company's  fiscal year ending  October 31,  1999,  and  requires  that
         comparative  information  from earlier years be restated to conform to
         the requirements of this standard.


2.       CREDIT AGREEMENTS

               The Company's credit line agreement expired December 31, 1997 and
               the Company does not plan to pursue a credit line at this time.


<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

The following  discussion  includes certain  forward-looking  statements.  Those
statements involve a number of risks and uncertainties, which could cause actual
results  to  differ  materially  from  the  expectation  stated,  including  the
following: slower than expected sales of Informedics' products, deterioration of
business  conditions  generally or  specifically  in the  health-care  industry,
regulatory  changes  involving  health  care or  medical  devices,  competitive
factors, price pressures and higher than expected turnover in key personnel.

Highlights

On July 29, 1997,  the Company  signed a letter of intent to merge into Mediware
Systems,  Inc.  ("Mediware") of Melville,  NY. The Company announced on December
19, 1997 the signing of an Agreement  and Plan of Merger to merge into  Mediware
in a stock  exchange  whereby one share of Mediware stock would be exchanged for
every 6.3 shares of the Company's stock. The merger is subject to Securities and
Exchange Commission review and the approval of the Company's shareholders.

The  Company's  operating  results  continued  to  improve  and it  realized  an
after-tax  profit of $188,525 in the first quarter of 1998 or an  improvement of
$450,369 over the same period in 1997. The  improvement was primarily the result
of cost-cutting measures which were fully realized in the first quarter of 1998.
Although the  Company's  total revenue of $803,770 for the first quarter of 1998
was $41,926 less than the first  quarter of 1997,  new sales of its main product
LifeLine was $108,503 better than the prior year's quarter.

In  December  1997,  the  Company  received  a  request  from  the Food and Drug
Administration ("FDA") for additional  information and clarifications  regarding
its Section 510(k) submission. The FDA requested the Company identify additional
safety critical  functions,  clarify the hardware platform on which its Lifeline
product is used, and expand its beta test  information.  The Company is actively
addressing  each of these  areas  and is  confident  that it will meet the FDA's
response date of April 5, 1998.

The Company is  currently  developing  a new  software  release for the LifeLine
product, which addresses the Year 2000 issue, expanded bar code labeling to meet
anticipated FDA requirements, and customer-recommended enhancements. The Company
has evaluated its anticipated  costs  associated with this release  (expected in
late summer 1998), including staffing levels,  distribution costs,  installation
requirements and training.  The Company's  management believes that it may incur
as much as $300,000 in costs  associated  with this  release.  The Company  will
account  for these  costs in  accordance  with its  normal  software  accounting
policies as discussed in its most recent 10-KSB filing.

In 1997, the Company established a valuation reserve against its deferred income
taxes which offset the income tax benefit for the first  quarter of 1997. In the
third quarter of 1997,  this reserve was  increased as the Company's  management
determined  that the benefit of the net operating  loss  carryforwards  were not
likely  to be  realized.  The  Company  was able to  utilize  some of these  net
operating loss  carryforwards  in the current  quarter to reduce the current tax
provision.

Results of Operations - Material Changes

Total product sales of $162,661 for the first quarter 1998 was $12,900 more when
compared to the first quarter 1997.  The increase was due to increased  sales of
LifeLine, offset by decreased sales of other products.

Customer service and support revenue  decreased $54,826 for the first quarter of
1998, when compared to the same period in 1997.  However,  1997 results included
one-time  programming service revenue associated with LifeLine and ClinicManager
product lines.  Hardware  support revenue  decreased 45% in the first quarter of
1998 when compared to first  quarter of 1997,  but the decline was mostly offset
by a new  technical  support  service  which is intended to replace the hardware
support service revenue.  The Company began marketing the new technical  support
service in the second quarter of 1997.

Hardware sales in the amount of $48,158 and associated  cost of products sold in
the first quarter of 1998 were comparable to the same period in 1997.

The cost of customer service and support decreased  $266,811,  while selling and
administrative  expenses  decreased  $209,645 in the first  quarter of 1998 when
compared to the first quarter of 1997. These cost  improvements  resulted from a
reduction in staff and other overhead costs.  Management  anticipates that these
costs will remain relatively stable over the remainder of fiscal 1998.
<PAGE>


Liquidity - Capital Resources

The  Company's  cash position grew from $207,692 on October 31, 1997 to $337,637
on January  31,  1998,  as the  Company  added  $130,661  of cash as a result of
operating activities,  used $24,049 for investing activities,  and added $23,333
from  financing  activities.  Based upon the  anticipation  of continued  steady
product  sales and reduced  operating  expenses,  management  believes  that the
Company's  current cash  position  will be  sufficient to fund its operating and
investment activities for the remainder of fiscal 1998.

As a result of the operating  profit in the first  quarter of 1998,  the Company
experienced  an improvement  of $248,960 in working  capital.  The Company had a
negative  working  capital on January  31,  1998 of  $348,185,  as compared to a
negative $597,145 on October 31, 1997. Excluding the deferred revenue liability,
which is a liability  for future  services,  the  Company's  working  capital on
January 31, 1998 was $1,205,890, compared to $595,223 on October 31, 1997.

Capital  expenditures for property additions were $2,325 in the first quarter of
1998  compared to $4,815 for the first quarter of 1997.  Management  anticipates
that capital  expenditures  for property  additions for the balance of 1998 will
remain low.

Capitalized  software  development  costs were $32,374 and $25,158 for the first
quarter of 1998 and 1997, respectively.  Management anticipates that capitalized
software  development  cost for the  remainder  of 1998  will  accelerate,  then
stabilize,  as the date of the next LifeLine product release  approaches in late
summer, 1998.

The Company's  credit line agreement  expired  December 31, 1997 and the Company
does not plan to pursue a credit line at this time.


                           Part II - Other Information




 Item 6.   Exhibits and Reports on Form 8-K

                    (a)  Exhibit.

                          27   Financial Data Schedule


                   (b)   Reports on Form 8-K

                           None












<PAGE>



                                   SIGNATURES



Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                         INFORMEDICS, INC.
                                         (Registrant)


Date March 13, 1998                      By /s/ John Tortorici
-------------------                      ----------------------
                                         John Tortorici, Chairman, President,
                                         Chief Executive Officer and
                                         Chief Financial Officer











<PAGE>


                                   FORM 10-QSB

                                  Exhibit Index

Exhibit

         27       Financial Data Schedule